Using Electronic Resources to provide High Quality, Low Cost Healthcare

Chris Wood, MD
Medical Director, Information Systems
(Brent James, MD MSTAT
AVP Quality Improvement)
Intermountain Healthcare
chris.wood@imail.org

Intermountain Healthcare

Intermountain Healthcare is a nonprofit system of hospitals, surgery centers, doctors, and clinics that serves the medical need of the State of Utah and South Eastern Idaho.

- 23 Hospitals
- 30,000 employees
- 150 clinics
- Over 600 physicians
- SelectHealth Insurance
  - Nearly 500,000 health plan enrollees

Intermountain is an internationally recognized system of hospitals, clinics and doctors focused on providing patients the highest quality of care at the lowest possible cost.

Sepsis

- Bacteria in the blood stream causing symptoms
- US National mortality rate around 27%

Mortality rate from Sepsis

2003
27%



2010
9.3%

Why focus on Quality?

40+% of all resource expenditures in hospitals is

quality-associated waste:

- *recovering from preventable foul-ups*
- *building unusable products*
- *providing unnecessary treatments*
- *simple inefficiency*

Andersen, C. 1991
James BC *et al*., 2006

Improve Quality or Add new Technology?

Mechanism	Quality	Cost	Forum	Potential Savings
Waste:				
Quality waste	↑	↓	internal	25-40%
Inefficiency waste	–	↓	internal	> 50%
Cost-benefit	↑	↑	society	(none)

Optimalist - Maximalist Argument



Fixes that Fail

- ***Problem:*** ***Prescription cost overruns for elderly Medicaid patients in New Hampshire***
- ***Plan:*** ***Pay for maximum of three drugs per outpatient***
- ***Results:***

Prescription drug costs:	***down***	***35%***	
Nursing home admits:	***up***	***120%***	***(to 2.2x)***
Hospitalizations:	***up***	***20%***	***(to 1.2x)***

- ***After 11 months, the plan was abandoned:***
  - ***rates returned to their old levels***
  - ***those institutionalized stayed institutionalized***

Soumerai *et. al* Effects of Medicaid drug-payment limits on admissions to hospitals and nursing homes. *New Engl J Med* 1991; 325(15):1072-7 (Oct 10).

Schroeder *et. al* On squeezing balloons: cost control fails again (editorial). *New Engl J Med* 1991; 325(15):1099-1100 (Oct 10).

The Chain of Effect for Quality



What to focus on?

- Pareto Principle
- 20% of the problems account for 80% of the waste/cost/mortality
- Define our most costly, high risk and high volume procedures and improve their quality
- Divide our key processes into sensible leadership teams that can oversee the workgroups that carry out the key processes

Organized around Key Clinical Processes



Structure: Implementing EBM



Projects: Post-Op Wound Infections



Deep Post-op Wound Infections

	1985	1986	1991
% prophylaxis given at optimal time	40	58	96
% Infections	1.8	0.9	0.4
Est. decrease in infections relative to 1985 rate	--	33	51
Est. savings at $14,000 per case (in thousands)	--	462	714

National standard: 2 - 4% deep post-op wound infection rate

LDSH Dept of Clinical Epidemiology

Deep Post-op Wound Infections

	1985	1994
% elective surgeries receiving prophylaxis	38.0	37.1
% receiving first dose 0-2 hrs before incision	40.0	99.1
% continuing prophylaxis 24 hrs after surgery	43.0	14.3
Mean number of doses per case	19.0	5.3

LDSH Dept of Clinical Epidemiology

Literature vs. Data
NICU admits by weeks gestation



Average Hours in Labor and Delivery



Interventions

- Educate Physicians about facts
- New Admission workflow
- New Admission tool
  - Calculates Estimated Date of Delivery (EDD)
  - Offers appointments after 39 weeks gestation
- Preserves Relationship between physician and patient

Elective Inductions <39 weeks



Elective Induction: Length of Labor



Elective Induction: Primary C-Section



Labor & Delivery Variable Cost





11 July 2003

Patient Worksheet

v1.0.21

PATIENT NAME	SEX	DOB	MMI#	MRN#
TEST, A A	F	09/01/1964	545073664	545073664

Problems

Hypothyroidism
s/p thyroidectomy
Diabetes mellitus type 2, insulin treatment
Hypertension
Atherosclerosis
Coronary artery disease

Active Medications

1. - Digitoxin, 0.1mg, Tablet; 3 Tablet(s) PO QD
2. - Entex LA (Guaifenesin/PPA [redacted]); 1 Tablet(s) PO BID

Preventive Care

CV Risk	Pap Smear
5%*(1.4x)**	No Data

Clinical Laboratory Data

HgbA1c (<=7.0)		UA Protein		uAlb/Cr (<30)		24 Urine Albumin (<30)	
No Data	-	06/01/2001	Negative	No Data	-	No Data	-
		12/18/2000	Positive				
		11/06/2000	Negative				

Serum Cr		Serum K		Lipid Profile		LDL (<100)	Trig (<200)	HDL (>35)	CHOL (<200)
04/26/2003	1.1	04/26/2003	4.2	04/26/2003		101	93	50	176
10/25/2002	2.0	02/05/2003	6.0	04/06/2003		154	85	41	212
02/27/2002	1.6	10/25/2002	4.5	02/24/2003		149	151	41	220
10/03/2001	2.3	01/29/2002	6.1	02/06/2003		168	189	33	239

TC/HDL Ratio		HCT		hsCRP		Homocysteine		Fasting Glucose	
04/26/2003	3.5	02/05/2003	35.9 %	04/06/2003	0.6 mg/l	04/06/2003	6 mcmol/l	02/25/2003	127
04/06/2003	5.2	10/02/2002	37.7 %	02/24/2003	1.2 mg/l			12/19/2002	127
02/24/2003	5.4	08/23/2002	45.0 %					01/02/2002	127
02/06/2003	7.2	07/19/2002	29.9 %					12/20/2001	127

Clinic Data

Date	Weight	BMI (<25)	Weight Class	Blood Pressure (<130/80)		Heart Rate	
No Data	-	-		01/25/2001	145/74 mmHg	01/25/2001	86

Last foot exam: No Data
Last dilated retinal exam: No Data -

Reminders

Preventive

* Predicted % Risk over 10 years of a cardiovascular event (MI, revascularization, CVA, death).
** Relative Risk over 10 years of a cardiovascular event compared to lowest risk category.
Pap and pelvic suggested every 3 years after three normal yearly Pap tests.
For Patients with known Cardiovascular Risk Class, Target LDL is <100.
Blood Pressure measurement is suggested for adults every two years.
Suggested follow-up for missing data: - Pap Smear
Pneumovax suggested for all patients age 65 and above, and all patients over age 2 with systemic chronic disease.

Diabetes

Suggest repeat Urine Albumin Test more than (>) 1 year since last test.
Last ALT = 28 on 4/26/2003 & AST = 66 on 4/26/2003
Suggested follow-up for missing data: - HgbA1c - Dialated Retinal Exam - Foot Exam - Weight

Hypertension

ACE Inhibitors (ACEI) or if ACEI intolerant, Angiotensin II Receptor Blockers (ARBs) or the combination of ACEI or ARBS and Diuretics are the

Individualized reports on performance compared to shared baselines

Diabetes Summary Report

Provider: Towner, Steven (168)

Period: Jan 2005 - Dec 2005

Patients Tested (Prop of Tot Pts%) - All Patients

	Provider	Region	System
HbA1c	188(97%)	1,582(90%)	25,429(83%)
LDL	190(98%)	1,658(94%)	26,040(85%)
Eye Exam	159(82%)	399(23%)	6,509(21%)
Microalbuminuria	159(82%)	1,236(70%)	14,969(49%)
Blood Pressure	188(97%)	1,248(71%)	15,344(65%)
Total Patients	**194**	**1,757**	**30,470**

1. LDL measures represent two years ending in the chose period. 2. Eye exam % calculated using Health Plans patients only. 3.Includes spot microalbumin, 24 hour urine for protein and microalbumin/creatine ratio within the reporting period, or any history of treatment for nephropathy. 4. Blood pressure data only available for physicians with access to Clinical Workstation and/or Results Review.













CONFIDENTIAL: This material is prepared pursuant to Utah Code Ann. 26-25-1 et. Seq. or Idaho Code Ann. 39-1392 et seq. for improvement of the quality of hospital and medical care rendered by hospitals or physicians.

Results: Poor HgbA1c Control drops



Results: Excellent HgbA1c Control



Allied Benefit: Improved Lipids



IS Tools

- Must integrate into the key workflow tools of clinicians and teams
- Must not damage workflow, should enhance it
- Must gather key data that reminds clinicians of best practice and allows monitoring of outcomes patients would care about

Evolving toward a High Quality Low Cost Healthcare organization



Discussion and Questions

chris.wood@imail.org